Effect of Magnesium on Remifentanil Induced Cough

Seoul National University

Status and phase

Unknown

Phase 4

Conditions

Cough

Treatments

Drug: Magnesium sulfate

Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT05237791

B-2201-731-001

Details and patient eligibility

About

The hypothesis of this study is that Magnesium sulfate pretreatment (50mg/kg) will reduce the incidence of cough and chest wall rigidity caused by remifentanil administration.

The purpose of this study was to investigate the effect of magnesium sulfate administered before induction of anesthesia on thoracic stiffness and cough response caused by opioid analgesics administered for general anesthesia.

Enrollment

78 estimated patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients aged 20-75 years of age who are undergoing surgery under general anesthesia using a laryngeal mask and who have consented to participate in this study among American Society of Anesthesiologists body grade 1 or 2

Exclusion criteria

When coughing may occur due to an underlying disease (upper respiratory infection, rhinitis, post nasal drip, asthma, chronic obstructive pulmonary disease, pneumonia, bronchitis, current smokers, etc.)
If you have kidney disease that can affect magnesium metabolism (glomerular filtration rate less than 60)
If you are taking opioid analgesics or magnesium for other reasons
Patients with hypermagnesemia
Patients with atrioventricular block (stages I-III) or other cardiac conduction disorders
Pregnant or lactating women
Patients with myasthenia gravis
Patients taking drugs that are contraindicated or interact with magnesium (barbitalates, aminoglycoside antibiotics, isoniazid, chlorpromazine, digoxin)
In case of hypersensitivity to magnesium
Patients with a history of hypersensitivity to propofol and any of its components
Patients with a history of hypersensitivity to remifentanil and other fentanyl analogues